Viewing nowCombinationOlmesartan Medoxomil and Amlodipine Tablets 5/20 mg
Olmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
HLB Pharmaceuticals Co., Ltd.

MFDS item code 202000345 · Approved 2020.01.21 · Insurance code 647304460
Treatment of essential hypertension not controlled by monotherapy
This medicine is used to effectively control blood pressure in patients with essential hypertension whose blood pressure is not sufficiently controlled with monotherapy using either Amlodipine or Olmesartan Medoxomil.
Take 1 tablet once daily with water, with or without food. If possible, it is recommended to take the medicine at the same time each day (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 mg. The maximum blood pressure-lowering effect occurs within 2 weeks of administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient’s blood pressure response into consideration. The recommended doses are as follows: - 5/20 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg as monotherapy. - 10/20 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg as monotherapy. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily. Use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients receiving dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced intravascular volume: In patients who may have reduced intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose while closely monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. In patients with hepatic impairment who are already receiving other antihypertensive medicines and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See Section 2. Patients Who Should Not Receive This Medicine under Precautions for Use.) ∘Older adults: In general, treatment should be started at a low dose. When adjusting the dose, the patient’s renal or cardiac function and comorbidities should be taken into consideration. In older adults, blood pressure should be monitored closely and more frequently.
The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.
This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy, so it must be discontinued immediately once pregnancy is confirmed. It should not be used in patients with allergies to any of the ingredients, those who are pregnant or nursing, severe liver disease, aortic stenosis, biliary obstruction, patients on kidney dialysis, in shock, or certain diabetic patients. In patients with fluid or salt depletion, hypotension can occur, so careful monitoring is required at the start of treatment. As vasodilation may lead to hypotension, patients with heart valve disease should be particularly cautious. Patients with heart failure or coronary artery disease may also experience worsening of their condition while taking this medication, so it should be used cautiously. Patients with impaired kidney function are at a higher risk of worsening kidney function, thus regular monitoring of kidney condition is necessary. Patients with reduced liver function should also be cautious while taking this medication. While taking this medication, various side effects may occur, including dizziness, headache, hypotension, edema, dyspepsia, rash, etc., and consultation with a doctor or pharmacist is advised if any abnormal symptoms develop. Regular blood tests and blood pressure measurements are required, especially due to the risks of hyperkalemia, changes in kidney function, and blood pressure drop. During pregnancy, this medication can have serious effects on the fetus, so those planning to become pregnant or who are pregnant should definitely consult their healthcare provider. If breastfeeding, it is advised to discontinue either breastfeeding or the medication due to the possibility of the drug being passed through breast milk. Its safety and efficacy have not been established in children under 18 years of age, so it is not recommended. In the elderly, due to possible impairment of kidney and liver function, treatment should start at a lower dose and be carefully monitored. In case of overdose, severe hypotension, vascular dilation, arrhythmias may occur, and immediate medical attention is required. This medication should be stored in a tightly closed container to protect from moisture and heat and kept out of reach of children, and it is best not to transfer the medication to another container. This medication may interact with other antihypertensive drugs or specific medications, so it is crucial to inform healthcare providers about any concomitant medications. In particular, taking this medication with grapefruit juice may enhance its effects, so it is advisable not to consume them together.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly closed container to protect it from air and moisture, ideally at room temperature between 1 and 30 degrees Celsius. This way of storage helps maintain the effectiveness of the medication for a longer period.
White round film-coated tablets
28 tablets/box [14 tablets/PTP×2]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
HLB Pharmaceuticals Co., Ltd.
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.